DK3912987T3 - Oprensningsplatform til bispecifikke antistoffer - Google Patents
Oprensningsplatform til bispecifikke antistoffer Download PDFInfo
- Publication number
- DK3912987T3 DK3912987T3 DK21170436.6T DK21170436T DK3912987T3 DK 3912987 T3 DK3912987 T3 DK 3912987T3 DK 21170436 T DK21170436 T DK 21170436T DK 3912987 T3 DK3912987 T3 DK 3912987T3
- Authority
- DK
- Denmark
- Prior art keywords
- bispecific antibodies
- purification platform
- purification
- platform
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/26—Cation exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029463P | 2014-07-26 | 2014-07-26 | |
| EP15750182.6A EP3172221B1 (en) | 2014-07-26 | 2015-07-24 | Purification platform for bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3912987T3 true DK3912987T3 (da) | 2023-05-01 |
Family
ID=53836215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21170436.6T DK3912987T3 (da) | 2014-07-26 | 2015-07-24 | Oprensningsplatform til bispecifikke antistoffer |
| DK15750182.6T DK3172221T3 (da) | 2014-07-26 | 2015-07-24 | Oprensningsplatform til bispecifikke antistoffer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15750182.6T DK3172221T3 (da) | 2014-07-26 | 2015-07-24 | Oprensningsplatform til bispecifikke antistoffer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10626142B2 (https=) |
| EP (2) | EP3912987B9 (https=) |
| JP (1) | JP6702967B2 (https=) |
| KR (1) | KR102440737B1 (https=) |
| CN (1) | CN107074906B (https=) |
| AR (1) | AR101262A1 (https=) |
| AU (1) | AU2015298156B2 (https=) |
| DK (2) | DK3912987T3 (https=) |
| EA (1) | EA036154B1 (https=) |
| ES (2) | ES2942533T3 (https=) |
| FI (1) | FI3912987T3 (https=) |
| IL (1) | IL255198B (https=) |
| MX (1) | MX377558B (https=) |
| MY (1) | MY187051A (https=) |
| PL (2) | PL3912987T3 (https=) |
| SG (2) | SG11201700157VA (https=) |
| TW (1) | TWI704155B (https=) |
| WO (1) | WO2016018740A2 (https=) |
| ZA (1) | ZA201700622B (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| US10294306B2 (en) * | 2015-05-28 | 2019-05-21 | Bio-Rad Laboratories, Inc. | Affinity ligands and methods relating thereto |
| AU2016381992B2 (en) * | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| CR20180554A (es) | 2016-04-28 | 2019-01-10 | Chugai Pharmaceutical Co Ltd | Preparaciones que contienen anticuerpos |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| EP4549463A3 (en) * | 2016-06-17 | 2025-07-30 | F. Hoffmann-La Roche AG | Purification of multispecific antibodies |
| WO2018038469A1 (ko) * | 2016-08-20 | 2018-03-01 | (주)아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| KR101933656B1 (ko) | 2016-08-20 | 2018-12-28 | (주) 아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN110461358A (zh) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
| CN119161488A (zh) | 2017-11-01 | 2024-12-20 | 中外制药株式会社 | 具有降低的生物活性的抗体变体和同种型 |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| GB201805142D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| MY207066A (en) * | 2018-08-17 | 2025-01-28 | Regeneron Pharma | Method and chromatography system for determining amount and purity of a multimeric protein |
| SG11202102713TA (en) * | 2018-09-21 | 2021-04-29 | Teneobio Inc | Methods for purifying heterodimeric, multispecific antibodies |
| WO2020066270A1 (ja) * | 2018-09-28 | 2020-04-02 | 株式会社カネカ | κ鎖可変領域を含む抗体および／または抗体断片の製造方法 |
| JP2022514122A (ja) | 2018-10-31 | 2022-02-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質を同定及び定量化する方法及びシステム |
| CA3110377A1 (en) | 2018-11-21 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Anti-staphylococcus antibodies and uses thereof |
| CN112996801A (zh) * | 2018-11-26 | 2021-06-18 | 北卡罗来纳州大学 | 用于捕获宿主细胞蛋白的肽配体 |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| IL319262A (en) | 2018-12-24 | 2025-04-01 | Sanofi Sa | Multispecific FAB pseudoproteins bind |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| EP3983015A1 (en) | 2019-06-11 | 2022-04-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
| WO2020252260A1 (en) * | 2019-06-13 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Methods for removing undesired components during multistage chromatographic processes |
| SG11202110968VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| CA3163017A1 (en) * | 2019-12-26 | 2021-07-01 | Daehae SONG | Method for purifying biologically active peptide by using protein a affinity chromatography |
| KR102834449B1 (ko) | 2019-12-27 | 2025-07-15 | 케이에스광학주식회사 | 투명한 방탄 적층 구조물 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| JP2024504388A (ja) * | 2021-01-25 | 2024-01-31 | ユーハン・コーポレイション | 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法 |
| GB202109246D0 (en) * | 2021-06-28 | 2021-08-11 | Cytiva Bioprocess R & D Ab | A method of separating bispecific antibodies |
| CN118414350A (zh) * | 2021-10-19 | 2024-07-30 | 阿特根公司 | 纯化具有igg fc结构域的融合蛋白的方法 |
| WO2023247468A2 (en) * | 2022-06-22 | 2023-12-28 | Puridify Limited | Kappa light chain-binding convection matrix |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| CN116769044A (zh) * | 2023-07-11 | 2023-09-19 | 康日百奥生物科技(苏州)有限公司 | 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法 |
| WO2025073922A1 (en) * | 2023-10-04 | 2025-04-10 | Sartorius Bia Separations D.O.O. | Enhanced chromatographic separations of components in a mixture by employing chaotropic elution |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
| WO2025131519A1 (en) * | 2023-12-21 | 2025-06-26 | Cytiva Bioprocess R&D Ab | Antibody separation with a vh3 binding separation matrix |
| WO2025173342A1 (ja) * | 2024-02-13 | 2025-08-21 | Jsr株式会社 | Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法 |
| WO2026075981A1 (en) * | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Methods of analyzing heterodimeric proteins |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8626413D0 (en) | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK0826695T3 (da) | 1996-09-03 | 2002-04-15 | Gsf Forschungszentrum Umwelt | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| WO2000018435A1 (de) | 1998-09-25 | 2000-04-06 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
| US7169903B2 (en) | 2001-12-21 | 2007-01-30 | Biosynexus Incorporated | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| US20030224000A1 (en) | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| ZA200710330B (en) | 2005-06-17 | 2009-12-30 | Wyeth Corp | Methods of purifying FC region containing proteins |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| SG149759A1 (en) * | 2007-07-10 | 2009-02-27 | Millipore Corp | Media for affinity chromatography |
| US20110166332A1 (en) * | 2008-09-12 | 2011-07-07 | Ge Healthcare Bio-Sciences Ab | Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| MY192182A (en) * | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2785414C (en) * | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Polypeptide modification method for purifying polypeptide multimers |
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| EP2500073A1 (en) * | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
| EP3517548A1 (en) * | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
-
2015
- 2015-07-21 AR ARP150102301A patent/AR101262A1/es active IP Right Grant
- 2015-07-23 TW TW104123813A patent/TWI704155B/zh active
- 2015-07-24 SG SG11201700157VA patent/SG11201700157VA/en unknown
- 2015-07-24 MX MX2017001217A patent/MX377558B/es active IP Right Grant
- 2015-07-24 EP EP21170436.6A patent/EP3912987B9/en active Active
- 2015-07-24 MY MYPI2017700080A patent/MY187051A/en unknown
- 2015-07-24 JP JP2017525320A patent/JP6702967B2/ja active Active
- 2015-07-24 DK DK21170436.6T patent/DK3912987T3/da active
- 2015-07-24 KR KR1020177003803A patent/KR102440737B1/ko active Active
- 2015-07-24 SG SG10201900661YA patent/SG10201900661YA/en unknown
- 2015-07-24 US US14/808,171 patent/US10626142B2/en active Active
- 2015-07-24 ES ES21170436T patent/ES2942533T3/es active Active
- 2015-07-24 WO PCT/US2015/041936 patent/WO2016018740A2/en not_active Ceased
- 2015-07-24 AU AU2015298156A patent/AU2015298156B2/en active Active
- 2015-07-24 EA EA201790247A patent/EA036154B1/ru not_active IP Right Cessation
- 2015-07-24 PL PL21170436.6T patent/PL3912987T3/pl unknown
- 2015-07-24 EP EP15750182.6A patent/EP3172221B1/en active Active
- 2015-07-24 DK DK15750182.6T patent/DK3172221T3/da active
- 2015-07-24 FI FIEP21170436.6T patent/FI3912987T3/fi active
- 2015-07-24 ES ES15750182T patent/ES2881026T3/es active Active
- 2015-07-24 PL PL15750182T patent/PL3172221T3/pl unknown
- 2015-07-24 CN CN201580040494.9A patent/CN107074906B/zh active Active
-
2017
- 2017-01-25 ZA ZA2017/00622A patent/ZA201700622B/en unknown
- 2017-10-22 IL IL255198A patent/IL255198B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3912987T3 (da) | Oprensningsplatform til bispecifikke antistoffer | |
| CL2018000370A1 (es) | Nuevos anticuerpos anti-pd-1 | |
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
| DK3608337T3 (da) | Bispecifikke T-celleaktiverende antigenbindende molekyler | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| DK3268390T3 (da) | Fremgangsmåder til oprensning af bispecifikke antistoffer | |
| EP3182987C0 (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
| EP3319984C0 (en) | TAU LINKING ANTIBODIES | |
| DK3160994T3 (da) | Multispecifikke antigenbindende proteiner | |
| DK3126395T3 (da) | Multispecifikke antistoffer | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| EP3319983C0 (en) | TAU LINKING ANTIBODIES | |
| MA40901A (fr) | Anticorps bispécifiques anti-tnf/anti-il-3 | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| LT3233813T (lt) | Į oksatiaziną panašių junginių gavimo būdai | |
| DK3215530T3 (da) | Forbedrede il-6 antistoffer | |
| EP3212232A4 (en) | TETRAVALENT TLR9 BISPECIFIC ANTIBODIES | |
| ITUB20155097A1 (it) | Anticorpi umanizzati anti-BAG3 | |
| LT3178931T (lt) | Anti-orai1 antikūnas | |
| LT3126391T (lt) | Hpa-1a antikūnai | |
| LT3628731T (lt) | Naujas antipresepsino antikūnas | |
| DK3197589T3 (da) | Fremgangsmåde til oprensning af væsker |